Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MNKD
MNKD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MNKD News
MannKind Presents New Afrezza Data at Diabetes Conference
Jun 08 2026
NASDAQ.COM
MannKind Releases New Data Supporting Afrezza Safety and Efficacy
Jun 05 2026
Newsfilter
MannKind Advances Clinical Trials for Inhaled IPF Therapy
Jun 05 2026
Yahoo Finance
Analysts' Perspectives on Multiple Companies' Stock Performances
Jun 05 2026
CNBC
Jim Cramer's Insights on Multiple Stocks
Jun 04 2026
CNBC
MannKind Advances Nintedanib DPI Clinical Trials
Jun 03 2026
Newsfilter
Investment Recommendations for Zoetis and Energy Transfer
Jun 03 2026
CNBC
FDA Approves MannKind's Afrezza for Children with Diabetes
May 31 2026
NASDAQ.COM
U.S. Stocks Hit Record Highs, Dell Shares Surge 33%
May 29 2026
stocktwits
FDA Approves Afrezza for Pediatric Use, First Inhaled Insulin
May 29 2026
stocktwits
MannKind Receives FDA Approval for Afrezza in Children
May 29 2026
Newsfilter
MannKind's Inhaled Insulin Approved for Children
May 29 2026
seekingalpha
FDA Approves Afrezza for Pediatric Diabetes Management
May 29 2026
Newsfilter
MannKind Set to Present Afrezza Data Amid FDA Decision
May 28 2026
stocktwits
MannKind Unveils New Afrezza Data Ahead of FDA Review
May 27 2026
Newsfilter
United Therapeutics' Tyvaso Shows Positive Results for Lung Fibrosis
May 19 2026
stocktwits
Show More News
